公开(公告)号：US20190178871A1

公开(公告)日：2019-06-13

申请号：US16301019

申请日：2017-05-10

申请人： BioNTech RNA Pharmaceuticals GmbH ,  TRO-Translationable Onkologie an der Unversitatsme dizin der Johannes Gutenberg-Universitat Mainz

发明人： Mathias Vormehr ,  Ugur Sahin ,  Barbara Schrörs ,  Martin Löwer ,  Sebastian Boegel

IPC分类号： G01N33/50 ,  G01N33/53 ,  G01N33/68 ,  A61P35/04

摘要： The present invention relates to methods for predicting peptides or polypeptides such as T cell epitopes useful for immunotherapy such as for vaccination. In particular, the present invention relates to methods for predicting whether peptides or polypeptides such as tumor-associated antigens or epitopes, in particular tumor-associated neoantigens or neoepitopes, are immunogenic and, in particular, useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.

公开(公告)号：US11156617B2

公开(公告)日：2021-10-26

申请号：US15550286

申请日：2016-02-09

申请人： BioNTech RNA Pharmaceuticals GmbH ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH

发明人： Ugur Sahin ,  Martin Löwer ,  Arbel D. Tadmor ,  Sebastian Boegel ,  Barbara Schrörs ,  Mathias Vormehr ,  Sebastian Kreiter

IPC分类号： G01N33/68 ,  G01N33/50 ,  A61K39/00

摘要： The present invention relates to methods for predicting T cell epitopes useful for vaccination. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic and, in particular, useful for vaccination, or for predicting which of such modifications are most immunogenic and, in particular, most useful for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and thus, in the context of personalized cancer vaccines.

公开(公告)号：US20210290746A1

公开(公告)日：2021-09-23

申请号：US17262180

申请日：2019-07-23

申请人： BioNTech RNA Pharmaceuticals GmbH ,  TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz

发明人： Ugur Sahin ,  Mathias Vormehr ,  Thomas Bukur

IPC分类号： A61K39/00 ,  C12Q1/6886 ,  A61P35/00

摘要： The present invention is in the field of tumor immunotherapy. In particular, the present invention provides individualized cancer vaccines specific for a patients tumor based on a transcriptome analysis in a tumor specimen of the patient for RNA transcripts which are excessively upregulated in one or more cancer cells of said patient. These individualized cancer vaccines when administered to the patient induce an immune response against tumor-associated antigens expressed in a tumor of the patient by the RNA transcripts which are excessively upregulated in one or more cancer cells of said patient. Due to the excessive upregulation of the RNA transcripts, the individualized cancer vaccines are effective for vaccination of a subject and for breaking the self-tolerance against tumor-associated antigens which are self-proteins in said subject.

公开(公告)号：US20220074948A1

公开(公告)日：2022-03-10

申请号：US17481243

申请日：2021-09-21

申请人： BioNTech RNA Pharmaceuticals GmbH ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-

发明人： Ugur Sahin ,  Martin Löwer ,  Arbel D. Tadmor ,  Sebastian Boegel ,  Barbara Schrörs ,  Mathias Vormehr ,  Sebastian Kreiter

IPC分类号： G01N33/68 ,  G01N33/50 ,  A61K39/00

摘要： The present invention relates to methods for predicting T cell epitopes useful for vaccination. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic and, in particular, useful for vaccination, or for predicting which of such modifications are most immunogenic and, in particular, most useful for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and thus, in the context of personalized cancer vaccines.

公开(公告)号：US20210292386A1

公开(公告)日：2021-09-23

申请号：US17262097

申请日：2019-07-19

申请人： BioNTech RNA Pharmaceuticals GmbH ,  TRON - Translationale Onkologie an der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz

发明人： Ugur Sahin ,  Mathias Vormehr ,  Lena Mareen Kranz ,  Sina Fellermeier-Kopf ,  Alexander Muik ,  Friederike Gieseke ,  Bodo Tillmann ,  Sonja Witzel

IPC分类号： C07K14/55 ,  A61P35/00 ,  A61K45/06 ,  A61K38/20 ,  A61K39/00 ,  A61K39/39

摘要： The invention relates to variants of interleukin-2 (IL2). In one embodiment, the IL2 variants activate effector T cells over regulatory T cells. In particular, the invention relates to a polypeptide comprising a mutein of human IL2 or of a functional variant of human IL2, wherein the human IL2 or functional variant thereof is substituted at at least a position having an acidic or basic amino acid residue in wild type human IL2 that contacts the alpha subunit of the αβγ IL2 receptor complex (I12Kαβγ). Alternatively, the mutein of human IL2 or of a functional variant of human IL2 comprises at least (i) one or more amino acid substitutions which reduce the affinity for the alpha subunit of II_2Kαβγ and (ii) one or more amino acid substitutions which enhance the affinity for II_2Kβγ. The invention also relates to polynucleotides coding for the polypeptides of the invention, host cells comprising the polynucleotides, pharmaceutical compositions comprising the polypeptides, polynucleotides or host cells, therapeutic or prophylactic methods of treatment using the polypeptides, polynucleotides, host cells or pharmaceutical compositions and medical preparations comprising the polypeptides, polynucleotides, host cells or pharmaceutical compositions.

公开(公告)号：US20210113606A1

公开(公告)日：2021-04-22

申请号：US16966422

申请日：2019-02-08

申请人： BioNTech RNA Pharmaceuticals GmbH ,  TRON - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz

发明人： Ugur Sahin ,  Lena Kranz ,  Mathias Vormehr ,  Mustafa Diken ,  Sebastian Kreiter ,  Bodo Tillmann

IPC分类号： A61K31/7105 ,  C07K14/55 ,  C07K14/54 ,  A61K39/00

摘要： The present disclosure relates to methods and compositions for inducing an immune response in a subject comprising co-administering to the subject RNA encoding peptides or proteins used for vaccination and RNA encoding IL-2 attached to a pharmacokinetic modifying group and/or RNA encoding IL-7 attached to a pharmacokinetic modifying group. The vaccine is particularly effective if an immune checkpoint inhibitor such as an anti-PD-L1 antibody is further administered. The present disclosure further relates to methods involving the target-specific delivery of a cytokine to a target organ or target tissue.